Semisolid Dosage Forms Manufacturing: Tools, Critical Process Parameters, Strategies, Optimization and Recent Advances
Semisolid Dosage Forms Manufacturing: Tools, Critical Process Parameters, Strategies, Optimization and Recent Advances
Semisolid Dosage Forms Manufacturing: Tools, Critical Process Parameters, Strategies, Optimization and Recent Advances
net/publication/322925854
CITATIONS READS
0 19,826
1 author:
Manoj Mishra
Shambhunath Institute of Pharmacy, Prayagraj, India
69 PUBLICATIONS 98 CITATIONS
SEE PROFILE
Some of the authors of this publication are also working on these related projects:
All content following this page was uploaded by Manoj Mishra on 04 February 2018.
Corresponding author
Md. Amman Maqbool
Shambhunath Institute of Pharmacy,
Jhalwa, Allahabad, Uttar Pradesh-211012, India.
Please cite this article in press as Md. Amman Maqbool et al. Semi Solid Dosage Forms Manufacturing: Tools, Critical Process
882
Parameters, Strategies, Optimization And Recent Advances. Indo American Journal of Pharmaceutical Research.2017:7(11).
Copy right © 2017 This is an Open Access article distributed under the terms of the Indo American journal of Pharmaceutical
Page
Research, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
www.iajpr.com
Vol 7, Issue 11, 2017. . Amman Maqbool et al. ISSN NO: 2231-6876
INTRODUCTION
Semisolids constitute a significant proportion of pharmaceutical dosage forms. They serve as carriers for drugs that are
topically delivered by way of the skin, cornea, rectal tissue, nasal mucosa, vagina, buccal tissue, urethral membrane, and external ear
lining [1]. A semisolid dosage form is advantageous in terms of its easy application, rapid formulation, and ability to topically deliver
a wide variety of drug molecules. Semisolids are available as a wide range of dosage forms, each having unique characteristics [2].
Topical semisolid dosage forms are normally presented in the form of creams, gels, ointments, or pastes. They contain one or more
active ingredients dissolved or uniformly dispersed in a suitable base and any suitable excipients such as emulsifiers, viscosity
increasing agents, anti microbial agents, antioxidants’, or stabilizing agents. The objective of this compiled data is to provide a clear
and in-depth knowledge of about various tools, strategies, critical process parameters and strategies of the manufacturing and
validation processes specific to semisolid dosage forms.
Ointments are semisolid preparations for external application to skin or mucous membranes. Their composition softens but
does not melt upon application to the skin. Therapeutically, ointments function as skin protectives and emollients, but they are used
primarily as vehicles for the topical application of drug substances. Creams are semisolid dosage forms that contain one or more drug
substances dissolved or dispersed in a suitable base, usually oil in- water emulsion or aqueous microcrystalline dispersion of long-
chain fatty acids or alcohols that are water washable and are cosmetically and aesthetically acceptable. Gels are semisolid systems that
consist of either suspensions of small inorganic particles or large organic molecules interpenetrated by a liquid. Pastes are semisolid
dosage forms that contain one or more drug substances incorporated in a base with large proportions of finely dispersed solids.
A wide range of raw materials is available for the preparation of a semisolid dosage form. Apart from the usual
pharmaceutical ingredients such as preservatives, antioxidants, and solubilizers, the basic constituents of a semisolid dosage form are
unique to its composition. The choice of suitable raw materials for a formulation development is made on the basis of the drug
delivery requirements and the particular need to impart sufficient emolliency or other quasi-medicinal qualities in the formulation. In
general, semisolid dosage forms are complex formulations having complex structural elements. Often they are composed of two
phases (oil and water), one of which is a continuous (external) phase, and the other of which is a dispersed (internal) phase. The active
ingredient is often dissolved in one phase, although occasionally the drug is not fully soluble in the system and is dispersed in one or
both phases, thus creating a three-phase system. The physical properties of the dosage form depend upon various factors, including the
size of the dispersed particles, the interfacial tension between the phases, the partition coefficient of the active ingredient between the
phases, and the product rheology. These factors combine to determine the release characteristics of the drug, as well as other
characteristics, such as viscosity [3].
Hydrophobic ointments:
Hydrophobic (lipophilic) ointments are usually anhydrous and can absorb only small amounts of water. Typical bases used
for their formulation are water-insoluble hydrocarbons such as hard, soft and liquid paraffin, vegetable oil, animal fats, waxes,
synthetic glycerides and polyalkyl siloxanes.
Water-emulsifying ointments:
Water-emulsifying ointments can absorb large amounts of water. They typically consist of a hydrophobic fatty base in which
883
a w/o agent, such as wool fat, wool alcohols, sorbitan esters, mono glycerides, or fatty alcohols can be incorporated to render them
hydrophilic. They may also be w/o emulsions that allow additional quantities of aqueous solutions to be incorporated. Such ointments
are used especially when formulating aqueous liquids or solutions.
Page
www.iajpr.com
Vol 7, Issue 11, 2017. . Amman Maqbool et al. ISSN NO: 2231-6876
Hydrophilic ointments:
Hydrophilic ointment bases are miscible with water. The bases are usually mixture of liquid and solid polyethylene glycols
(macrogols) [4].
Creams:
Creams are homogeneous, semi-solid preparations consisting of opaque emulsion systems. Their consistency and rheological
properties depend on the type of emulsion, either water-in-oil (w/o) or oil-in –water (o/w), and on the nature of the solids in the
internal phase. Creams are intended for the application to the skin or certain mucous membranes for protective, therapeutic, or
prophylactic purposes, especially where an occlusive effect is not necessary.
Gels:
Gels are usually homogeneous, clear, semi-solid preparations consisting of a liquid phase within a three-dimensional
polymeric matrix with physical or sometimes chemical cross-linkage by means of suitable gelling agents.
Hydrophobic gels:
Hydrophobic gel (oleogel) bases usually consist of liquid paraffin with polyethylene or fatty oils gelled with colloidal silica
or aluminium or zinc soaps.
Hydrophilic gels:
Hydrophilic gels (hydrogel) bases usually consist of water, glycerol, or propylene glycol gelled with suitable agents such as
tragacanth, starch, cellulose derivatives, carboxyvinyl polymers, and magnesium aluminium silicates.
Pastes:
Pastes are homogeneous, semi-solid preparations containing high concentrations of insoluble powdered substances (usually
not less than 20%) dispersed in a suitable base. The pastes are usually less greasy, more absorptive, and stiffer in consistency than
ointments because of the large quantity of powdered ingredients present. Some pastes consist of a single phase, such as hydrated
pectin, and others consist of a thick, rigid material that does not flow at body temperature. The pastes should adhere well to the skin.
In many cases they form a protective film that controls the evaporation of water.
Poultices:
A poultice is an ancient form of topical medication also known as a cataplasma. It is a soft mass of vegetable constituents or
clay, usually heated before application. Kaolin poultice BP is prepared by mixing and heating dried, heavy kaolin and boric acid with
glycerine. After cooling, the aromatic substances are incorporated with stirring. The product is spread on a dressing and applied hot to
the skin.
(Fig 1: Basic raw materials used in the development of various semisolid dosage forms)
884
Page
www.iajpr.com
Vol 7, Issue 11, 2017. . Amman Maqbool et al. ISSN NO: 2231-6876
Ointment:
For topical:
Vectical (TM):
Psoriasis is a chronic skin disorder that affects 2 to 3 percent of the U.S. population. It is characterized by thick, red, scaly
patches of skin and caused by an abnormally high growth rate of skin cells that form thick, dry scales (plaques).
Vectical (TM) Ointment is indicated for the topical treatment of mild to moderate plaque psoriasis in patients 18 years and
older [5] Vectical (TM) Ointment contains calcitriol, the naturally-occurring, active form of vitamin D3, and is one of the only vitamin
D3 products shown in clinical trials to be well-tolerated even when used on sensitive skin fold areas [6].
Creams:
Creams containing microspheres:
Microspheres are white powders that under a microscope show every particle to be spherical. In cosmetics, microspheres are
used for: enhanced feel, optical blurring, absorption/ delivery of materials. Microspheres can alter the tactile qualities of a cosmetic
like initial contact, application, after feel etc.
Gel:
The word ‘‘gel’’ is derived from ‘‘gelatin,’’ and both ‘‘gel’’ and ‘‘jelly’’ can be traced back to the Latin gelu for ‘‘frost’’ and
gelare, meaning ‘‘freeze’’ or ‘‘congeal”. The USP defines gels (sometimes called jellies) as semisolid systems consisting of either
suspensions made up of small inorganic particles, or large organic molecules interpenetrated by a liquid. Most topical gels are
prepared with organic polymers such as carbomers which impart an aesthetically pleasing, clear sparkling appearance to the product
and are easily washed off the skin with water. In a typical polar gel, a natural or synthetic polymer builds a three dimensional matrix
throughout a hydrophilic liquid. Typical polymers used include the natural gums Tragacanth, carrageenan, pectin, agar and alginic
acid; semi synthetic materials such as methylcellulose, hydroxyl ethyl cellulose, hydroxyl propyl methyl cellulose, and carboxy
methyl cellulose; and the synthetic polymer, carbopol may be used. Gels are compatible with many substances and may contain
penetration enhancers for anti-inflammatory and anti-nauseant medications [10].
Nanosphere gel:
Tyrosine-derived nanospheres have demonstrated potential as effective carriers for the topical delivery of lipophilic
molecules. Gel formulation containing nanospheres was developed for effective skin application and enhanced permeation. Carbopol
and HPMC hydrophilic gels were evaluated for dispersion of these nanospheres. Sparingly water soluble diclofenac sodium (DS) and
lipophilic Nile Red were used as model compounds.
885
of absorption. However, drug release from the gel must be sustained if benefits are to be gained from the prolonged contact time.
www.iajpr.com
Vol 7, Issue 11, 2017. . Amman Maqbool et al. ISSN NO: 2231-6876
It was possible to control the release of uncharged drug substances by including surfactants that form micelles in the gel. This
release depended on lipophilic interactions between the drug and the polymer and/or the micelles. Controlled-release formulations of
charged drugs could be designed by mixing the drugs with oppositely charged surfactants in certain ratios. In this way, vesicles in
which the drug and surfactant constituted the bilayer formed spontaneously. The vesicle formation was affected by the presence of
polymer, and very small vesicles that gave a slow release rate were formed when a lipophilically modified polymer was used. The gels
were also evaluated in the Ussing chamber using porcine nasal mucosa. The rate of transport of drugs through the mucosa could be
controlled by the rate of release from the formulation. Furthermore, the Ussing chamber could be used to evaluate the potential
toxicity of formulations [11, 12].
Amphiphilic gels:
Amphiphilic gels can prepared by mixing the solid gelator like sorbitan monostearate or sorbitan monopalmitate and the
liquid phase like liquid sorbitan esters or polysorbate and heating them at 60°C to form a clear isotropic sol phase, and cooling the sol
phase to form an opaque semisolid at room temperature Amphiphilic gel microstructures consisted mainly of clusters of tubules of
gelator molecules that had aggregated upon cooling of the sol phase, forming a 3D network throughout the continuous phase. The gels
demonstrated thermoreversibility. Gelation temperature and viscosity increased with increasing gelator concentration, indicating a
more robust gel network. At temperatures near the skin surface temperature, the gels softened considerably; this would allow topical
application.This study has demonstrated the formation/preparation of stable, thermoreversible, thixotropic surfactant gels
(amphiphilogels) with suitable physical properties for topical use.
Hydrophilic gels:
Hydrophilic gels are bicoherent systems composed of the internal phase made of a polymer producing a coherent three-
dimensional net-like structure, which fixes the liquid vehicle as the external phase. Intermolecular forces bind the molecules of the
solvent to a polymeric net, thus decreasing the mobility of these molecules and producing a structured system with increased viscosity.
The physical and chemical bonds binding the particles of the internal phase provide a relatively stable structure, which can originate
by swelling of solid polymers, or by decreasing the solubility of the polymer in a solution. An important group of gels used in
pharmacy are hydrophilic gels, or hydrogels, usually made of hydrophilic polymers, which under certain conditions and polymer
concentration, jellify. Attention of pharmaceutical research now concentrates primarily on hydrophilic gels, as this dosage form seems
to be prospective for the development of modern drugs based on systems with prolonged and controlled release of active ingredients.
Bioadhesive Gels:
Chitosan bioadhesive gel was formulated for nasal delivery of insulin. A nasal perfusion test was carried out to study the
toxicity of four absorption enhancers like saponin, sodium deoxycholate, ethylendiamine tetra-Acetic Acid (EDTA) and lecithin. The
gels contained 4000 Iu/dl insulin, 2 or 4% of low and medium molecular weight of chitosan, and lecithin or EDTA. Drug release was
studied by a membraneless diffusion method and bio adhesion by a modified tensiometry test.
www.iajpr.com
Vol 7, Issue 11, 2017. . Amman Maqbool et al. ISSN NO: 2231-6876
Advantages of thermo sensitive sol-gel reversible hydrogels over conventional hydrogels are:
a) It is easy to mix pharmaceutical solution rather than semisolids
b) Biocompatibility with biological systems
c) Convenient to administer
d) The pharmaceutical and biomedical uses of such sol-gel transition include solubilization of low molecular- weight hydrophobic
drugs.
e) Release can be in a controlled fashion.
f) Helps to deliver labile bio macromolecule such as proteins and genes.
g) Immobilization of cells
h) And tissue engineering [14].
batch size from the pilot or clinical size to commercial level must exist with similar equipment. Guidance from FDA’s Scale-Up and
Post approval Changes Semisolids (SUPAC-SS) Working Group provides the basis of comparison for the design and operating
principles of equipment [17].
Page
www.iajpr.com
Vol 7, Issue 11, 2017. . Amman Maqbool et al. ISSN NO: 2231-6876
Mixing times
Optimizing mixing time requires identifying the minimum time required for ingredients to dissolve and the maximum mixing
time before product failure (e.g., when viscosity begins to drop). For polymeric gels, particularly acrylic acid-based types, over-
mixing, especially high shear, can break down the polymer's structure. In an emulsion, over-mixing may cause the product to separate
prematurely, resulting in a drastic decline in viscosity.
888
Page
www.iajpr.com
Vol 7, Issue 11, 2017. . Amman Maqbool et al. ISSN NO: 2231-6876
Flow rates
Optimizing flow rate involves determining the amount of shear or throughput needed. For example, a water-in oil emulsion
may require a slower addition speed than a traditional, oil-in-water emulsion, and the flow rate must be modified appropriately. Care
must be taken for any product using a pump. Overhearing can occur if the formulation is pumped too quickly. If pumping is too slow,
the formulation will experience extra time in an in-line homogenizer, thus also exposing the formulation to additional shear [20]. Two
processes that require experimentation to optimize flow rates are the use of a powder ejection system and an in-line homogenizer.
Theoretical calculations can determine the number of times a sample will pass through either, but actually performing the experiments
is necessary to achieve optimal results. Raw material dispersers and in-line homogenizers require proper flow rates for optimal usage.
If the product is not flowing through a disperser at the proper rate, there will not be enough suction for properly incorporating the
powders. Suction can be tested by measuring the vacuum being pulled at the inlet of the disperser with a vacuum/pressure gauge.
Monitoring the flow rate when using an in-line homogenizer is necessary in order to calculate the theoretical number of times the
product passes through it.
DESIGN OF EXPERIMENTS
The major process parameters useful for design of experiments is provided in Table 1.
Batch Emulsification Time of Temp. of High shear Temp. CMM Initial 1 week
RPM emulsification emulsification on cool down switch on speed viscosity viscosity
CMM
1 High X minutes 75-80ο C Low Low X rpm 110000 70000
2 High X minutes 75-80ο C Low Medium X rpm 100000 80000
3 High X minutes 75-80ο C Low High X rpm 100000 70000
4 High X minutes 75-80ο C Medium Low X rpm 120000 110000
5 High X minutes 75-80ο C Medium Medium X rpm 70000 60000
6 High X minutes 75-80ο C Medium High X rpm 60000 50000
7 High X minutes 75-80ο C High Low X rpm 120000 120000
8 High X minutes 75-80ο C High Medium X rpm 100000 70000
9 High X minutes 75-80ο C High High X rpm 90000 70000
Process validation:
Documented evidence, a high degree of assurance that a specific process will consistently produce a product that meets its
pre-determined specification and quality characteristics.
www.iajpr.com
Vol 7, Issue 11, 2017. . Amman Maqbool et al. ISSN NO: 2231-6876
Validation protocol
Written plan describing the process to be validated, including production equipment.
How validation will be conducted
Objective test parameter
Product characteristics
Predetermine specification
Factors affecting acceptable result
Mixing of liquids
Equipment: Kettle and tank fitted with agitator
Page
www.iajpr.com
Vol 7, Issue 11, 2017. . Amman Maqbool et al. ISSN NO: 2231-6876
Dispersing
Equipment: Homogenizers, Colloid mill, or ultrasonic device
Product testing
Validation testing of bulk and finished product must be based on testing standard release criteria and in process testing criteria
Routine QC release testing should be performed on a routine sample.
These samples should be taken separately from the validation samples. Validation sampling and testing typically is 3 to 6 ime the
usual QC sampling
Sampling plan
Samples must be representative of each filling nozzle.
Monitoring output
Particle size Consideration:
Control of particle morphology and particle size are important parameters to attain high quality drug product manufacture and
control procedure. Particle size distribution for most disperse system should be in the range of 0.2- 20 microns.
Viscosity:
The Viscometer- Calibrated to measure the apparent viscosity of the disperse system at equilibrium at a given temperature to
establish system reproducibility.
Content uniformity
Most important parameter governing product stability and process control of the disperse system. In ointment/cream
891
formulation are more dependent on particle size, shear rate, and mixing efficiency in order to attain and maintain uniformity of the
active drug component (usually the internal phase).
Page
www.iajpr.com
Vol 7, Issue 11, 2017. . Amman Maqbool et al. ISSN NO: 2231-6876
Preservative effectiveness
Incorporating a USP antimicrobial preservative testing procedure or microbial limit test into formal validation of aqueous
dispersion. Determination of bio burden for validation and production batches can also be used to establish appropriate validated
cleaning procedure for the facilities and equipment used in manufacture of disperse system.
Dissolution testing
It is primary used as a quality control procedure to determine product uniformity. Secondary for assessing the in vivo
absorption of the drug in terms of a possible in vitro/vivo correlation. For cream/ointments, the Franz in vitro flow through diffusion
cell has been modified by using silicon rubber membrane barrier to stimulate percutaneous dissolution unit for testing purpose.
Validation report
Standard format
CONCLUSION
Many kind of formulations can be designed by semi solid dosage form and for the same in depth problems occurred in
various steps must be controlled. To prepare a successful product batch studies and testing should be done in a broad level. Extensive
future research studies should be conducted for more precise and accurate product.
Conflict of Interest:
All authors have no conflict of interest.
REFERENCES
1. Idson B, Lazarus J. Semisolids in the Theory and Practice of Industrial Pharmacy. In: Lachman L, Lieberman HA, Kanig JL
editors; Varghese Publishing House, Bombay, India, 1991: pp. 534-563.
2. Block LH. Medicated Applications. In Gennaro AR; Remington: The Science and Practice of Pharmacy. Mack Publishing
Company, Easton, Pennsylvania, 1995: pp. 1577-1597.
3. Lieberman HA, Rieger MM, Banker GS. Pharmaceutical Dosage Forms: Disperse System, 2nd edition, Volume 3, Marcel
Dekker: New York, 1989, pp. 473-511.
4. The International Pharmacopoeia, World Health Organization 2013, 4 th edition.
5. O. Carl, Formulating with microspheres. Technical seminar, April 14, 2008.
6. Galderma Wins FDA Approval for Vectical (TM) Ointment: A Novel Topical Therapy for Mild-to-Moderate Plaque Psoriasis.
Fierce Biotech, The biotech industries daily monitor 2009.
7. Pinedo G, Zarate AJ, Inostroza G, Meneses X, Falloux E, Molina O, Molina ME, Bellolio F, Zúñiga A. New treatment for faecal
incontinence using zinc-aluminium ointment: a double-blind randomized trial. Colorectal Disease 2012; 14(5):596-598.
8. Patel P, Tyagi S, Patel CJ, Patel J, Chaudhari B, Kumar U: Recent advances in novel semisolid dosage forms: An overview.
Journal of biomedical and pharmaceutical research 2013; 2(1):9-14.
9. Remington: The Science and Practice of Pharmacy. Mack publishing Company, 19thEdition, Vol. 1, 1995: pp. 304-310.
10. Bhowmik D, Gopinath H, Kumar BP, Duraivel S, Kumar KPS: Controlled Release Drug Delivery Systems. The Pharma
Innovation 2012; 1(10):24-32.
11. Paulsson M. Controlled Release Gel Formulations for Mucosal Drug Delivery. Acta Universitatis Upsaliensis, Comprehensive
Summaries of Uppsala Dissertations from the Faculty of Pharmacy, 2001: pp. 259.
12. Patel P, Tyagi S, Patel CJ, Patel J, Chaudhari B, Kumar U. Recent advances in novel semisolid dosage forms: An overview.
Journal of Biomedical and Pharmaceutical Research 2013; 2(1):10-11.
13. Shyamoshree B and Maity S: Preparation and characterisation of mucoadhesive nasal gel of venlafaxine hydrochloride for
treatment of anxiety disorders. Indian Journal of Pharmaceutical Sciences 2012; 74 (6): 564-570.
14. Prashant K, Vivek R, Dixit D, Pranav P. Hydrogels as a drug delivery system and applications: A review. International Journal of
Pharmacy and Pharmaceutical Sciences 2012; 4(1):1-7.
15. Agalloco JP, Carleton FJ; Validation of Pharmaceutical Processes; 3rd edition, New York Informa Healthcare USA, 2007: pp.
417-428.
892
16. Idson B, Lazarus J; Semisolids. In The Theory and Practice of Industrial Pharmacy. In Lachman L, Lieberman HA, Kanig JL
editors, Varghese Publishing House, Mumbai, India, 1991: pp. 534-563.
17. FDA; Guidance for Industry, Nonsterile Semisolid Dosage Forms, Scale-Up and Post approval Changes: Chemistry,
Page
Manufacturing, and Controls, in vitro Release Testing and in vivo Bioequivalence Documentation, Rockville, MD, May 1997.
www.iajpr.com
Vol 7, Issue 11, 2017. . Amman Maqbool et al. ISSN NO: 2231-6876
18. Block LH. Medicated Applications. In Gennaro AR editor; Remington: The Science and Practice of Pharmacy. 19th edition,
Mack Publishing Company, Easton, Pennsylvania, 1995: pp. 1590-1597.
19. Zatz JL, Kushla P; Gels. In In: Lieberman HA, Rieger MM, Banker GS, editors; Pharmaceutical Dosage Forms: Disperse
Systems. Volume 2, 2nd edition, New York: Marcel Dekker, 1989: pp. 495-510.
20. Collett M, Aulton EA; Text Book of Pharmaceutical Practice. 3nd edition, ELBS Publishers, London, 2009.
21. Lachman L, Lieberman HA, Kenig JL. The Theory & Practice of Industrial Pharmacy. 3rd edition, Varghese Publishing house,
1987.
22. Nash RA, Wachter AH; Pharmaceutical Process Validation; 3rd edition.
54878478451171117
893
Page
www.iajpr.com
View publication stats